The WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment informs health care professionals in Member States on how to improve treatment and care for patients with drug susceptible TB (DS-TB).

This update by WHO aims to use the best available evidence on the treatment of drug-susceptible TB and interventions to ensure adequate patient care and support in order to inform policy decisions made in these technical areas by national TB control programme managers, national policy-makers and medical practitioners in a variety of ...

This update by WHO aims to use the best available evidence on the treatment of drug-susceptible TB and interventions to ensure adequate patient care and support in order to inform policy decisions made in these technical areas by national TB control programme managers, national policy-makers and medical practitioners in a variety of ...

All patients with DS-TB without documented resistance to isoniazid and rifampicin may be treated using the 6-month rifampicin-containing regimen 2HRZ (E)/4HR, which comprises isoniazid, rifampicin, pyrazinamide and ethambutol, for 2 months followed by isoniazid and rifampicin for 4 …

With the availability of new evidence on the treatment of drug susceptible TB (DS-TB), WHO has recently updated the DS-TB treatment guidelines by convening a guideline development group meeting in April 2021 and then by releasing the WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug- Susceptible Tuberculosis Treatment in 2022.

RECOMMENDED DOSES OF FIRST-LINE ANTITUBERCULOSIS DRUGS FOR ADULTS. The WHO-recommended formulations of anti-TB drugs and fixed-dose combinations (FDCs) of drugs appear in the WHO Model List of Essential Medicines (available at www.who.int/medicines/publications/essentialmedicines/en).

2016年8月10日 · This guideline provides recommendations on the clinical and public health management of tuberculosis in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis.

In children and adolescents aged between 3 months and 16 years with non-severe TB, a 4-month treatment course is recommended. This recommendation is based on the evidence from the SHINE trial, a large phase III trial to evaluate duration of TB treatment in children with non-severe drug-susceptible TB.

Adverse drug reactions (ADRs) to tuberculosis (TB) drugs are a significant concern for medical professionals and health authorities. Adverse events due to drug-resistant TB (DRTB) treatment are among the most important reasons for treatment interruption.

DSTB is a case where a person is infected with TB bacteria that are susceptible to all first line anti-TB drugs. It means that all of the first line TB drugs will be effective as long as they are taken properly and regularly. This type of TB has the best prognosis and the shortest treatment duration.